Analysts expect Cumberland Pharmaceuticals Inc to report revenue of 10.20 M for Q4 22, against a range of 9.47 M to 10.93 M. The most recent reported quarter, Q3 22, came in at 11.41 M.
| Metric | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 10.54 M | 9.06 M | 8.07 M | 8.32 M | 11.18 M | 10.30 M | 11.41 M | - | - | - | - | - |
| High Estimate | 8.88 M | 8.95 M | 9.35 M | 13.36 M | - | - | - | 10.93 M | 13.14 M | 11.96 M | 16.07 M | 15.28 M |
| Low Estimate | 7.55 M | 7.66 M | 7.75 M | 12.10 M | - | - | - | 9.47 M | 11.10 M | 10.49 M | 13.81 M | 13.67 M |
| Consensus Estimate | 8.21 M | 8.31 M | 8.55 M | 12.73 M | - | - | - | 10.20 M | 12.12 M | 11.23 M | 14.94 M | 14.47 M |
Analysts expect Cumberland Pharmaceuticals Inc to report earnings per share of -0.22 for Q4 22, against a range of -0.23 to -0.21. The most recent reported quarter, Q3 22, came in at -0.03.
| Metric | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.01 | 0.08 | -0.07 | -0.26 | -0.09 | -0.09 | -0.03 | - | - | - | - | - |
| High Estimate | -0.12 | -0.13 | -0.11 | -0.01 | - | - | - | -0.21 | -0.14 | -0.20 | -0.08 | -0.28 |
| Low Estimate | -0.14 | -0.15 | -0.13 | -0.01 | - | - | - | -0.23 | -0.16 | -0.22 | -0.10 | -0.30 |
| Consensus Estimate | -0.13 | -0.14 | -0.12 | -0.01 | - | - | - | -0.22 | -0.15 | -0.21 | -0.09 | -0.29 |